Aclaris’s second crack at a topical Jak
But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.
Stock market correction sends biopharma back to the start of 2021
Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
2020 wins top of the froths for biotech stocks
It's official: dramatic share price jumps in response to clinical data have become more common.
Japanese drugmakers stand out at the nine-month mark
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
Concert squares up to Pfizer in alopecia Jak bout
Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
